Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable.

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

Pfizer’s experimental drug, berobenatide, is designed to stay attached longer to a blood protein called albumin, helping ...

Pfizer presented data ​on Saturday that showed a monthly dose of an experimental obesity drug it acquired through ‌its ...

Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence.

Pfizer Inc. recently presented detailed Phase 2b results for berobenatide (PF’3944), an investigational once-weekly and ...

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks ...

A symbol of American pharmaceutical innovation for nearly two centuries, Pfizer now faces the challenges of AI adoption and ...

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data ...

Pfizer (NYSE:PFE | PFE Price Prediction) is one of those names where the headline narrative (COVID hangover, patent cliff) keeps overshadowing what is actually a defensive cash machine trading at a ...

Vertex Pharmaceuticals announced the FDA has accepted its biologics license application submission for povetacicept, an ...